Diponkar Banerjee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Diponkar Banerjee has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Brian Skinnider
University of British Columbia, Vancouver, British Columbia, Canada
1 shared publication - Faisal Mohamed Fadlelmola
Center for Bioinformatics and Systems Biology, Faculty of Science, University of Khartoum, Khartoum, Sudan
1 shared publication - Jason B Cohn
Samuel Lunenfeld Research Institute, Toronto, Canada
1 shared publication - Minglong Zhou
Centre for Translational and Applied Genomics (CTAG), Department of Pathology and Laboratory Medicine, British Columbia Cancer Agency, Vancouver Cancer Centre, BC V5Z 4E6, Canada
1 shared publication - Randy D. Gascoyne
Centre for Lymphoid Cancer, BC Cancer Agency, Vancouver, BC, Canada
1 shared publication
Latest Publications
- Open Access
- 24 January 2008
- Published by Springer Nature in Molecular Cancer
- Vol. 7 (1) , 12
Constitutive overexpression of a novel 21 kDa protein by Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphomas
CD30, a 120 kDa surface phosphorylated protein is a member of tumour necrosis/nerve growth factor receptor (TNF/NGFR) family and constitutively expressed by Hodgkin and Reed-Sternberg (HRS) cells of Hodgkin lymphoma (HL) and the neoplastic cells of Anaplastic Large Cell Lymphoma (ALCL). A disease-specific protein marker is yet to be identified in Hodgkin lymphoma cells. In order to define HL-specific biomarkers, novel murine monoclonal antibodies were developed in our laboratory.
- 24 January 2008
- Published by Springer Nature in Molecular Cancer
- Vol. 7 (1) , 12
Open AccessConstitutive overexpression of a novel 21 kDa protein by Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphomas
CD30, a 120 kDa surface phosphorylated protein is a member of tumour necrosis/nerve growth factor receptor (TNF/NGFR) family and constitutively expressed by Hodgkin and Reed-Sternberg (HRS) cells of Hodgkin lymphoma (HL) and the neoplastic cells of Anaplastic Large Cell Lymphoma (ALCL). A disease-specific protein marker is yet to be identified in Hodgkin lymphoma cells. In order to define HL-specific biomarkers, novel murine monoclonal antibodies were developed in our laboratory.